Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature

다국어 초록 (Multilingual Abstract)

Objective: The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer.
Methods: We retrospectively reviewed seven patients with stage IVb cervical cancer who have been primarily treated with TC. The activity and the toxicity were evaluated. Response rate was the main endpoint.
Results: Overall, the treatment of TC was well tolerated. The overall response rate was 71.4% (2 complete response, 3partial response). Although grade 3-4 hematologic toxicities were observed in 3 out of 7 patients (42.8%), no patients experienced grade 3-4 non-hematologic toxicities. When we combined our present results with the previous reports,the overall response rate of TC is 63.6%.
Conclusion: TC is active and well tolerated in patients FIGO stage IVb cervical cancer. This combination may be considered as an initial treatment regimen in this patient population.

참고문헌 (Reference)

1 Secord AA, "Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer" 12 : 31-36, 2007

2 Mabuchi S, "The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy" 113 : 200-204, 2009

3 Coleman RL, "The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials" 110 : 77-80, 2008

4 Long HJ 3rd, "Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study" 23 : 4626-4633, 2005

5 Moore DH, "Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study" 116 : 44-49, 2010

6 Monk BJ, "Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study" 27 : 4649-4655, 2009

7 Moore DH, "Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study" 22 : 3113-3119, 2004

8 Sit AS, "Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix" 22 : 368-373, 2004

9 National Comprehensive Cancer Network, "NCCN practice guideline in oncology 2008" National Comprehensive Cancer Network

10 Long HJ 3rd, "Management of metastatic cervical cancer: review of the literature" 25 : 2966-2974, 2007

11 Barbera L, "Management of early and locally advanced cervical cancer" 36 : 155-169, 2009

12 Piver MS, "First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix: a phase II study" 75 : 334-337, 1999

13 US National Institutes of Health, "ClinicalTrials.gov: a randomized phase III trial of paclitaxel plus cisplatin versus paclitaxel plus carboplatin in stage IVb, persistent, or recurrent cervical cancer" US National Institutes of Health

14 Omura GA, "Chemotherapy for stage IVB or recurrent cancer of the uterine cervix" 21 : 123-126, 1996

15 Tinker AV, "Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience" 98 : 54-58, 2005

16 Nishio S, "Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma" 19 : 497-503, 2008

17 McGuire WP 3rd, "A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study" 7 : 1462-1468, 1989

18 Moore KN, "A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer" 105 : 299-303, 2007